echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Is presbyopia saved?

    Is presbyopia saved?

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 25, AbbVie/Allergan announced that it had submitted a new drug listing application (NDA) for AGN-190584 (1.


    Presbyopia is a common progressive eye disease that reduces the ability of the eyes to focus on close objects and usually affects people over 40 years old.


    AbbVie's application is mainly based on the results of two phase III studies code-named GEMINI 1 and GEMINI 2.


    AGN-190584 is an improved new drug formulation of pilocarpine (a cholinergic muscarinic receptor agonist), which was developed as a once-daily eye drop for the treatment of presbyopia.


    According to 1399 questionnaire surveys of middle-aged people aged 40-55 in the United States, 90% of the population suffers from presbyopia.


    At present, there is no approved drug for presbyopia in the world, and there are currently 3 drugs in phase III research.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.